Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.73 |
| ▸ | MAOA | P21397 | 8/20 | 0.73 |
| ▸ | TGM2 | P21980 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323142 | 0.98 | MAOB (0.71) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL9096300 | 0.98 | MAOB (0.71) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL9112917 | 0.98 | MAOB (0.71) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL3742475 | 0.95 | MAOB (0.70) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL7377143 | 0.89 | TGM2 (0.69) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL8671077 | 0.85 | MAOB (0.83) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL16112078 | 0.83 | MAOB (0.70) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL17274921 | 0.82 | MAOB (0.65) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL2246979 | 0.82 | TGM2 (0.73) | MAOBMAOATGM2ALDH1A1CES1 | |
| SCHEMBL28797509 | 0.80 | MAOB (0.59) | MAOBMAOATGM2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578757-B1 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2014-10-22 | — | — | EP | disclosed |
| EP-1578757-B1 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2014-10-22 | — | — | EP | disclosed |
| US-7863428-B2 | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2011-01-04 | — | — | US | disclosed |
| US-7863428-B2 | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2011-01-04 | — | — | US | disclosed |
| US-7863428-B2 | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2011-01-04 | — | — | US | disclosed |
| CN-100558738-C | Fluorogenic substrate of enzyme and preparation method thereof | TIBOTEC BVBA (BE) | 2009-11-11 | — | — | CN | disclosed |
| WO-2007132280-A1 | ISATIN AND ITS DERIVATIVES FOR USE AS A MEDICAMENT | Szegedi Tudományegyetem (HU) | 2007-11-22 | — | — | WO | disclosed |
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | TIBOTEC BVBA (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | TIBOTEC BVBA (BE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | TIBOTEC BVBA (BE) | 2007-02-15 | — | — | US | disclosed |
| CN-1732180-A | Fluorogenic enzyme substrates and methods of preparation | TIBOTEC BVBA (BE) | 2006-02-08 | — | — | CN | disclosed |
| EP-1578757-A2 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | Tibotec BVBA (BE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058787-A2 | FLUOROGENIC ENZYME SUBSTRATES AND METHODS OF PREPARATION | TIBOTEC BVBA (BE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037234-A1 | fluorophores containing 2-(3H-4-oxo-6-n-pentyl-2-quinazolinyl)-4-n-pentylphenyl phosphate; hydrolases; improved cell permeability; photostability | DNPEP, HEXD, NPEPPS | MAOB 1091/4885MAOA 887/4885TGM2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.